ADReCS

Pharmaceutical Information

Drug Name	Cytarabine
Drug ID	BADD_D00560
Description	A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
Indications and Usage	For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia. Cytarabine is indicated in combination with [daunorubicin] for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.[L32843]
Marketing Status	approved; investigational
ATC Code	L01BC01
DrugBank ID	DB00987
KEGG ID	D00168
MeSH ID	D003561
PubChem ID	6253
TTD Drug ID	D07XSN
NDC Product Code	71288-168; 61703-304; 55512-0026; 25021-229; 61703-319; 68083-343; 71288-108; 12848-1003; 71288-109; 71288-169; 58623-0026; 61703-303; 63323-120; 68083-337; 61703-305; 67430-075; 25021-223
UNII	04079A1RDZ
Synonyms	Cytarabine \| Arabinosylcytosine \| Cytosine Arabinoside \| Arabinoside, Cytosine \| Arabinofuranosylcytosine \| Aracytidine \| beta-Ara C \| beta Ara C \| Cytarabine Hydrochloride \| Cytosar \| Cytosar-U \| Cytosar U \| Ara-C \| Ara C \| Aracytine \| Cytonal

Chemical Information

Molecular Formula	C9H13N3O5
CAS Registry Number	147-94-4
SMILES	C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Bronchial secretion retention	22.03.02.008	0.000168%		Not Available
Liver injury	12.01.17.012; 09.01.07.022	0.000392%		Not Available
Hyperammonaemic encephalopathy	14.10.01.006; 17.13.01.005	0.000112%		Not Available
Organising pneumonia	22.01.02.008	0.000168%		Not Available
Low birth weight baby	18.04.02.003	0.000112%		Not Available
Cytarabine syndrome	15.03.04.016; 08.05.02.010	-	-	Not Available
Gastrointestinal sounds abnormal	07.01.01.002	0.000112%		Not Available
Acute haemorrhagic conjunctivitis	24.07.05.006; 11.05.14.001; 06.04.01.009	-	-	Not Available
Brain injury	19.07.03.007; 17.11.01.003	0.000112%		Not Available
Oropharyngeal pain	22.12.03.016; 07.05.05.004	0.000470%
Acute kidney injury	20.01.03.016	0.003425%
Use of accessory respiratory muscles	22.12.02.015	0.000246%		Not Available
Foetal growth restriction	18.03.01.002	0.000392%
Posterior reversible encephalopathy syndrome	17.13.02.007	0.001052%
Central nervous system haemorrhage	24.07.04.016; 17.08.01.035	0.001343%		Not Available
Drug-induced liver injury	12.03.01.044; 09.01.07.023	0.000504%		Not Available
Multiple organ dysfunction syndrome	08.01.03.057	0.002071%
Jugular vein thrombosis	24.01.02.007	0.000168%		Not Available
Obstruction gastric	07.13.04.002	0.000168%
Systemic mastocytosis	16.21.01.008; 01.13.01.008; 10.02.01.014	0.000112%		Not Available
Intracranial hypotension	17.02.05.036; 12.01.10.008	0.000112%		Not Available
Transient acantholytic dermatosis	23.03.03.069	0.000246%		Not Available
Multi-organ disorder	08.01.03.074	0.000168%		Not Available
Bone marrow necrosis	24.04.09.002; 01.05.01.012	0.000168%		Not Available
Acute myeloid leukaemia recurrent	16.01.05.004; 01.10.05.004	0.000392%		Not Available
Leukaemia recurrent	16.01.03.005; 01.10.03.005	0.000112%		Not Available
Acute lymphocytic leukaemia recurrent	16.01.01.003; 01.10.01.003	0.000246%		Not Available
Renal ischaemia	24.04.11.005; 20.01.07.015	0.000112%		Not Available
Oncologic complication	16.32.03.025	0.000112%		Not Available
Seizure like phenomena	17.12.03.030	0.000112%		Not Available

The 13th Page First Pre 13 14 Next Last Total 14 Pages